{"filing":{"accession_number":"0001193125-26-338438","cik":"0001707502","ticker":"SLDB","company_name":"Solid Biosciences Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"d177624d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526338438/d177624d8k.htm"},"events":[{"id":24685,"run_id":22381,"accession_number":"0001193125-26-338438","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"The Company filed a prospectus supplement on August 6, 2026 to offer and sell up to $200.0 million of common stock pursuant to an Amended and Restated Sales Agreement with Jefferies LLC. This represents a material dilutive equity issuance under an ATM (at-the-market) offering program, with the Company having already issued $85.0 million in shares under the prior prospectus supplement. The filing of a new prospectus supplement to increase the offering capacity signals a significant capital raise that would materially dilute existing shareholders.","company_name":"Solid Biosciences Inc.","ticker":"SLDB","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":25330,"accession_number":"0001193125-26-338438","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Company filed a prospectus supplement on August 6, 2026 to offer and sell up to $200.0 million of common stock pursuant to an Amended and Restated Sales Agreement with Jefferies LLC. This represents a material dilutive equity issuance under an ATM (at-the-market) offering program, with the Company having already issued $85.0 million in shares under the prior prospectus supplement. The filing of a new prospectus supplement to increase the offering capacity signals a significant capital raise that would materially dilute existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:37:37.452436+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25330,"accession_number":"0001193125-26-338438","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Company filed a prospectus supplement on August 6, 2026 to offer and sell up to $200.0 million of common stock pursuant to an Amended and Restated Sales Agreement with Jefferies LLC. This represents a material dilutive equity issuance under an ATM (at-the-market) offering program, with the Company having already issued $85.0 million in shares under the prior prospectus supplement. The filing of a new prospectus supplement to increase the offering capacity signals a significant capital raise that would materially dilute existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:37:37.452436+00:00","company_name":"Solid Biosciences Inc.","ticker":"SLDB","filing_date":"2026-08-06"}]}